The hallmark of 
adaptive immunity is antigen presentation to T cells. This takes place 
through specialised receptors known as major histocompatibility 
complexes (MHC I or II). In addition, lipids get presented to natural 
killer T (NKT) cells through the CD1 family of receptors and this 
property is not restricted to antigen-presenting cells.
Emerging evidence indicates that the microsomal triglyceride 
transfer protein (MTP) is required for proper loading of lipids onto the
 CD1 receptor. Scientists on the EU-funded HEPATOCYTE MTP project wished
 to investigate this axis of antigen presentation in the liver. In this 
context, they generated transgenic mice lacking MTP specifically in 
hepatocytes and assessed antigen presentation.
MTP knockout hepatocytes exhibited a severe defect in the 
presentation of both endogenous and microbial-derived lipids to NKT 
cells. This was attributed to CD1 instability, causing defects in the 
tertiary structure of the receptor complex and an inability to bind 
antigen.
These findings were extrapolated to patients with 
abetalipoproteinemia, a metabolic disease caused by mutations in MTP. 
Dendritic cells from these patients show enhanced degradation of CD1 and
 lack of lipid presentation. Furthermore, researchers discovered that 
MTP regulated the homeostasis of liver-resident immune cells and was 
essential in the defence against Hepatitis B virus.
Overall, the key HEPATOCYTE MTP discovery was that MTP plays a 
central role in immune responses where lipid presentation is essential, 
such as in Hepatitis B infection. Given the millions of patients 
worldwide with chronic Hepatitis B, this result has significant 
implications for the development of therapeutic strategies for their 
treatment.
EN 
CS
DE
ES
FR
HU
IT
PL
PT
РУ
SK
TR
УК
AR
中文





